Thomas S. Rogers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thomas S. Rogers has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- José Mauro Kutner
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
2 shared publications - Mark K. Fung
University of Vermont Medical Center Burlington Vermont USA
2 shared publications Rebecca Wilcox
Department of Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington, VT, USA
2 shared publications- Ryszard Pogłód
Institute of Hematology and Transfusion Medicine, Warsaw, Poland
2 shared publications Allahna Elahie
Hamilton Health Sciences, Hamilton, Ontario, Canada
1 shared publicationAlyssa Ziman
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA
1 shared publication
Latest Publications
- Open Access
- 1 January 2019
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Autopsy Case Reports
- Vol. 9 (3) , e2019090
High-grade B-Cell lymphoma with MYC and BCL6 rearrangements associated with Richter transformation of chronic lymphocytic leukemia
Richter transformation (RT), or Richter syndrome, is defined as the transformation of chronic lymphocytic leukemia (CLL) to an aggressive B-cell lymphoma. The vast majority, up to 99%, transform into diffuse large B-cell lymphoma (DLBCL), with a small subset (<1%) becoming classical Hodgkin lymphoma. Approximately half of RT cases progress through a pathway involving dysregulation of C-MYC. High-grade B-cell lymphoma (HGBL) is a recent diagnostic category of aggressive B-cell lymphomas set forth in the updated 2017 WHO Classification of Hematopoietic and Lymphoid Tissues. HGBL with MYC and BCL2 and/or BCL6 rearrangements, formerly "double-hit" and "triple-hit" lymphomas, comprise the majority of HGBL cases. Patients with HGBL have a worse prognosis than those with diffuse large B-cell lymphoma. We present a case of RT with rearrangements of MYC and BCL6. To our knowledge, there are no reported cases of RT with a "double-hit" lymphoma genotype.
- 1 January 2019
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Autopsy Case Reports
- Vol. 9 (3) , e2019090
Open AccessHigh-grade B-Cell lymphoma with MYC and BCL6 rearrangements associated with Richter transformation of chronic lymphocytic leukemia
Richter transformation (RT), or Richter syndrome, is defined as the transformation of chronic lymphocytic leukemia (CLL) to an aggressive B-cell lymphoma. The vast majority, up to 99%, transform into diffuse large B-cell lymphoma (DLBCL), with a small subset (<1%) becoming classical Hodgkin lymphoma. Approximately half of RT cases progress through a pathway involving dysregulation of C-MYC. High-grade B-cell lymphoma (HGBL) is a recent diagnostic category of aggressive B-cell lymphomas set forth in the updated 2017 WHO Classification of Hematopoietic and Lymphoid Tissues. HGBL with MYC and BCL2 and/or BCL6 rearrangements, formerly "double-hit" and "triple-hit" lymphomas, comprise the majority of HGBL cases. Patients with HGBL have a worse prognosis than those with diffuse large B-cell lymphoma. We present a case of RT with rearrangements of MYC and BCL6. To our knowledge, there are no reported cases of RT with a "double-hit" lymphoma genotype.
- Open Access
- 1 January 2019
- Published by Elsevier in Academic Pathology
- Vol. 6
Design and Implementation of a Pathology-Specific Handoff Tool for Residents
- 1 January 2019
- Published by Elsevier in Academic Pathology
- Vol. 6
Open AccessDesign and Implementation of a Pathology-Specific Handoff Tool for Residents
- 27 July 2018
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 45 (11) , 858-863
Pediatric cutaneous T‐cell post‐transplant lymphoproliferative disorder: Case report and review of the literature
Post‐transplant lymphoproliferative disease (PTLD) is a rare lymphoid and/or plasmacytic proliferation that occurs in the context of immunosuppression because of solid organ transplantation (SOT) and allogeneic hematopoietic stem cell transplantation (HSCT). PTLD is the most common cancer in children who receive a SOT or HSCT, occurring in up to 13% of these patients. The majority of PTLDs are extracutaneous B‐cell lymphomas, with only 12% to 14%, representing the T‐cell phenotype. PTLDs can involve the skin and behave like an aggressive lymphoma, and are among the most serious and potentially fatal complications of transplantation. Here we present a case report and review of the literature of pediatric cutaneous PTLD.
- 27 July 2018
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 45 (11) , 858-863
Pediatric cutaneous T‐cell post‐transplant lymphoproliferative disorder: Case report and review of the literature
Post‐transplant lymphoproliferative disease (PTLD) is a rare lymphoid and/or plasmacytic proliferation that occurs in the context of immunosuppression because of solid organ transplantation (SOT) and allogeneic hematopoietic stem cell transplantation (HSCT). PTLD is the most common cancer in children who receive a SOT or HSCT, occurring in up to 13% of these patients. The majority of PTLDs are extracutaneous B‐cell lymphomas, with only 12% to 14%, representing the T‐cell phenotype. PTLDs can involve the skin and behave like an aggressive lymphoma, and are among the most serious and potentially fatal complications of transplantation. Here we present a case report and review of the literature of pediatric cutaneous PTLD.
- Open Access
- 1 December 2017
- Published by Wolters Kluwer Health in Medicine
- Vol. 96 (50) , e8649
Paraproteinemic keratopathy in monoclonal gammopathy of undetermined significance treated with primary keratoprosthesis
We report a case of paraproteinemic keratopathy associated with monoclonal gammopathy of undetermined significance, treated with keratoprosthesis as a primary penetrating procedure. Histopathological findings and a world literature review are presented. A 74 year old female recently diagnosed with monoclonal gammopathy undetermined significance presented with progressive blurry vision bilaterally. Examination revealed corneal opacities consistent with paraproteinemic keratopathy. Corneal transplantation with the Boston Type I keratoprosthesis was performed on the right and, a year later, on the left. Visual outcomes were good. Histopathological staining of host corneal buttons were consistent with monoclonality, and electron microscopy revealed fibrillar extracellular aggregates within intervening normal stroma. Corneal deposits may be the only manifestation of monoclonal gammopathy of undetermined significance in patients who are otherwise systemically asymptomatic. Ophthalmologists who encounter corneal opacities may order the appropriate diagnostic studies to determine the presence of occult systemic disease. Risk of graft failure after penetrating keratoplasty from recurring opacities is high, so keratoprosthesis as a primary penetrating procedure may afford superior long-term outcomes. Host corneal buttons retrieved from penetrating keratoplasty or corneal biopsy may be sent for histopathological examination to confirm the diagnosis.
- 1 December 2017
- Published by Wolters Kluwer Health in Medicine
- Vol. 96 (50) , e8649
Open AccessParaproteinemic keratopathy in monoclonal gammopathy of undetermined significance treated with primary keratoprosthesis
We report a case of paraproteinemic keratopathy associated with monoclonal gammopathy of undetermined significance, treated with keratoprosthesis as a primary penetrating procedure. Histopathological findings and a world literature review are presented. A 74 year old female recently diagnosed with monoclonal gammopathy undetermined significance presented with progressive blurry vision bilaterally. Examination revealed corneal opacities consistent with paraproteinemic keratopathy. Corneal transplantation with the Boston Type I keratoprosthesis was performed on the right and, a year later, on the left. Visual outcomes were good. Histopathological staining of host corneal buttons were consistent with monoclonality, and electron microscopy revealed fibrillar extracellular aggregates within intervening normal stroma. Corneal deposits may be the only manifestation of monoclonal gammopathy of undetermined significance in patients who are otherwise systemically asymptomatic. Ophthalmologists who encounter corneal opacities may order the appropriate diagnostic studies to determine the presence of occult systemic disease. Risk of graft failure after penetrating keratoplasty from recurring opacities is high, so keratoprosthesis as a primary penetrating procedure may afford superior long-term outcomes. Host corneal buttons retrieved from penetrating keratoplasty or corneal biopsy may be sent for histopathological examination to confirm the diagnosis.
- 14 October 2017
- Published by Wiley in Transfusion
- Vol. 58 (1) , 151-157
An international investigation into AB plasma administration in hospitals: how many AB plasma units were infused? The HABSWIN study
BACKGROUND: Typical practice is to transfuse group‐specific plasma units; however, there are situations where group AB plasma (universal donor) is issued to group A, B, or O recipients. If demand for group AB plasma exceeds collections, there is potential for shortage. This project explored the patterns of group AB plasma utilization at hospitals around the world.STUDY DESIGN AND METHODS: The study had two phases: a survey that inquired about hospital group AB plasma inventory, policies, and transfusion practices and a retrospective review of 2014 calendar year data where participants submitted information on plasma disposition including ABO group of unit and recipient, transfusion location, and select indications. Recruitment occurred through snowball sampling. Descriptive analyses were performed.RESULTS: Survey data were received from 25 centers across 10 countries; of those, 15 participants contributed to the data collection component. These 15 centers transfused a total of 43,369 AB plasma units during the study period. Only 1496 of 5541 (27%) group AB plasma units were transfused to group AB recipients. Transfusion policies, practices, and patterns were variable across sites.CONCLUSION: Group AB plasma units are frequently transfused to non‐AB recipients. Whether transfusing 73% of group AB plasma units to non‐AB recipients is the ideal inventory management strategy remains to be determined.
- 14 October 2017
- Published by Wiley in Transfusion
- Vol. 58 (1) , 151-157
An international investigation into AB plasma administration in hospitals: how many AB plasma units were infused? The HABSWIN study
BACKGROUND: Typical practice is to transfuse group‐specific plasma units; however, there are situations where group AB plasma (universal donor) is issued to group A, B, or O recipients. If demand for group AB plasma exceeds collections, there is potential for shortage. This project explored the patterns of group AB plasma utilization at hospitals around the world.STUDY DESIGN AND METHODS: The study had two phases: a survey that inquired about hospital group AB plasma inventory, policies, and transfusion practices and a retrospective review of 2014 calendar year data where participants submitted information on plasma disposition including ABO group of unit and recipient, transfusion location, and select indications. Recruitment occurred through snowball sampling. Descriptive analyses were performed.RESULTS: Survey data were received from 25 centers across 10 countries; of those, 15 participants contributed to the data collection component. These 15 centers transfused a total of 43,369 AB plasma units during the study period. Only 1496 of 5541 (27%) group AB plasma units were transfused to group AB recipients. Transfusion policies, practices, and patterns were variable across sites.CONCLUSION: Group AB plasma units are frequently transfused to non‐AB recipients. Whether transfusing 73% of group AB plasma units to non‐AB recipients is the ideal inventory management strategy remains to be determined.
- 7 November 2016
- Published by Wiley in Transfusion
- Vol. 56 (11) , 2901-2903
Permanently removing AB red blood cells from inventory: a case for conserving scarce AB plasma
- 7 November 2016
- Published by Wiley in Transfusion
- Vol. 56 (11) , 2901-2903
Permanently removing AB red blood cells from inventory: a case for conserving scarce AB plasma
- Open Access
- 27 July 2016
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 146 (2) , 238-243
The Crossmatch/Issue Ratio
Objectives: To understand the worldwide scope of RBC crossmatching and issuing practices and measure efficiency using a novel quality indicator, the crossmatch/issue (C/I) ratio. Methods: An electronic survey was disseminated to hospital transfusion services collecting details about RBC crossmatching and issuing practices. Respondents were asked to enumerate the number of RBCs crossmatched and issued at their institutions during the 2014 calendar year to calculate the C/I ratio. Results: Fifty-two survey responses were received, mostly from North American transfusion services (28/52, 54%). The electronic crossmatch was the most common technique (n = 29), and most respondents performed the crossmatch at the time that an order for RBCs was received in the transfusion service (even if an order to issue the RBCs was not received). Data to calculate the C/I ratio were supplied by 22 respondents, and the mean ± SD was 1.30 ± 0.34. There was no difference in C/I ratios between services that use the electronic or serologic crossmatch techniques ( P = .49). The ratio was the same at the four sites that crossmatch RBCs at the time of issue compared with the time of order receipt (mean ± SD, 1.11 ± 0.09 vs. 1.35 ± 0.36, respectively; P = .19). Conclusions: Electronic crossmatching is common, and the C/I ratio can be an indicator of efficiency.
- 27 July 2016
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 146 (2) , 238-243
Open AccessThe Crossmatch/Issue Ratio
Objectives: To understand the worldwide scope of RBC crossmatching and issuing practices and measure efficiency using a novel quality indicator, the crossmatch/issue (C/I) ratio. Methods: An electronic survey was disseminated to hospital transfusion services collecting details about RBC crossmatching and issuing practices. Respondents were asked to enumerate the number of RBCs crossmatched and issued at their institutions during the 2014 calendar year to calculate the C/I ratio. Results: Fifty-two survey responses were received, mostly from North American transfusion services (28/52, 54%). The electronic crossmatch was the most common technique (n = 29), and most respondents performed the crossmatch at the time that an order for RBCs was received in the transfusion service (even if an order to issue the RBCs was not received). Data to calculate the C/I ratio were supplied by 22 respondents, and the mean ± SD was 1.30 ± 0.34. There was no difference in C/I ratios between services that use the electronic or serologic crossmatch techniques ( P = .49). The ratio was the same at the four sites that crossmatch RBCs at the time of issue compared with the time of order receipt (mean ± SD, 1.11 ± 0.09 vs. 1.35 ± 0.36, respectively; P = .19). Conclusions: Electronic crossmatching is common, and the C/I ratio can be an indicator of efficiency.
- 1 February 2016
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 14 (2) , A29-A30
A Rare Neoplasm Presents as Incidental Dilatation of the Common Bile Duct
- 1 February 2016
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 14 (2) , A29-A30
A Rare Neoplasm Presents as Incidental Dilatation of the Common Bile Duct
- Open Access
- 17 December 2015
- Published by F1000 Research Ltd in F1000Research
- Vol. 4, 1469
Recent Advances in Preventing Adverse Reactions to Transfusion
The spectrum of adverse reactions to blood product transfusion ranges from a benign clinical course to serious morbidity and mortality. There have been many advances in technologies and transfusion strategies to decrease the risk of adverse reactions. Our aim is to address a few of the advancements in increasing the safety of the blood supply, specifically pathogen reduction technologies, bacterial contamination risk reduction, and transfusion associated acute lung injury risk mitigation strategies.
- 17 December 2015
- Published by F1000 Research Ltd in F1000Research
- Vol. 4, 1469
Open AccessRecent Advances in Preventing Adverse Reactions to Transfusion
The spectrum of adverse reactions to blood product transfusion ranges from a benign clinical course to serious morbidity and mortality. There have been many advances in technologies and transfusion strategies to decrease the risk of adverse reactions. Our aim is to address a few of the advancements in increasing the safety of the blood supply, specifically pathogen reduction technologies, bacterial contamination risk reduction, and transfusion associated acute lung injury risk mitigation strategies.